Tasimelteon
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
N-([(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide | |
Clinical data | |
Pregnancy cat. | ? |
Legal status | ? |
Routes | Oral |
Identifiers | |
CAS number | 609799-22-6 |
ATC code | None |
PubChem | CID 10220503 |
UNII | SHS4PU80D9 |
Chemical data | |
Formula | C15H19NO2 |
Mol. mass | 245.3 g/mol |
|
|
(what is this?) (verify) |
Tasimelteon (BMS-214,778) is a drug which is under development for the treatment of insomnia and other sleep disorders.[1] It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to older drugs such as ramelteon.[2] It has been through Phase III trials successfully and was shown to improve both onset and maintenance of sleep, with few side effects.[3]
A year-long (2011-2012) study at Harvard is testing the use of tasimelteon in blind subjects with non-24-hour sleep-wake disorder.[4]
[edit] See also
Discovery and development of melatonin receptor agonists
[edit] References
- ^ 'Time-bending drug' for jet lag. BBC News. 2 December 2008
- ^ Vachharajani Nimish N., Yeleswaram Krishnaswamy, Boulton David W. (April 2003). "Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist". Journal of Pharmaceutical Sciences 92 (4): 760–72. doi:10.1002/jps.10348. PMID 12661062.
- ^ Shantha MW Rajaratnam, Mihael H Polymeropoulos, Dennis M Fisher, Thomas Roth, Christin Scott, Gunther Birznieks, Elizabeth B Klerman (2009-02-07). "Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials". The Lancet 373 (9662): 482–491. doi:10.1016/S0140-6736(08)61812-7. PMID 19054552. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2808%2961812-7/abstract. Retrieved 2010-02-23.
- ^ Audio interview with Joseph Hull of Harvard, spring 2011
|
This sedative-related article is a stub. You can help Wikipedia by expanding it. |